Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As news broke of the potential sale of genetic testing company 23andMe, lawmakers in Congress are demanding answers on how the company protects users’ sensitive data.

The sale is raising concerns about the privacy of the millions of individuals who have shared their genetic information with 23andMe.

Members of Congress are calling for hearings to investigate the data privacy safeguards that 23andMe has in place, as well as questioning the potential impact of the sale on users’ privacy rights.

There are concerns that the sale of 23andMe could result in a breach of user data or that the new owners may not prioritize data privacy protections.

Lawmakers are also seeking information on how 23andMe stores and shares genetic data, as well as how the company obtains consent from users to use their information.

The potential sale of 23andMe has reignited the debate on data privacy and the need for stronger regulations to protect consumers’ sensitive information.

Some lawmakers are calling for increased transparency and accountability from companies that collect and store large amounts of personal data.

The hearings are expected to shed light on the current state of data privacy protections in the genetic testing industry and highlight the need for better oversight and regulation.

Consumers are advised to review their privacy settings and consider the risks of sharing sensitive data with companies like 23andMe before making a decision to participate in genetic testing.

Stay tuned for updates on the congressional hearings and developments in the 23andMe sale as lawmakers continue to push for answers on data privacy.